Richard Eskew, Executive Vice President and General Counsel at Accolade, Inc. (NASDAQ:ACCD), reported a notable stock transaction in a recent SEC filing. On November 4, Eskew sold 336 shares of Accolade common stock at an average price of $3.149 per share, totaling approximately $1,058. This sale was conducted to cover tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs), as per the filing.
In addition to the sale, Eskew acquired shares through the conversion of RSUs. On November 1, he gained 1,145 shares of common stock through RSU conversions, although these transactions did not involve any cash exchange, as each RSU converted into one share of common stock. Following these transactions, Eskew now holds 52,515 shares of Accolade common stock directly.
In other recent news, Accolade Inc (NASDAQ:ACCD). has seen a series of revisions in its stock price targets by several analyst firms, notwithstanding its strong financial performance. Wells Fargo (NYSE:WFC) adjusted its price target to $6.00, citing concerns over delayed contract closures potentially affecting future revenues. However, the firm maintains that Accolade's revenue targets for FY26 remain achievable with moderate growth in Annual Contract Value.
Accolade reported a robust Q2 2025 performance, exceeding revenue expectations with a total of $106.4 million and surpassing its adjusted EBITDA guidance. The company also confirmed its FY25 revenue guidance between $460 million to $475 million and projected a positive adjusted EBITDA of $15 million to $20 million.
Analyst firms Stephens, Canaccord Genuity, Truist Securities, and BofA Securities revised their price targets for Accolade while maintaining Buy ratings. Stephens and Canaccord Genuity adjusted their models to reflect a 12% revenue growth for Accolade in FY25 and FY26. Despite third-quarter guidance falling below estimates, Canaccord Genuity expressed confidence in Accolade's ability to meet performance guarantees and secure new business.
Truist Securities reduced its price target to $7.50, and BofA Securities reduced its target to $5.75, both maintaining a Buy rating. Accolade's management has expressed optimism about a strong pipeline with diversification across employers, health plans, and government segments. However, slower revenue growth is anticipated in FY26 due to staggered launches.
InvestingPro Insights
As Richard Eskew's recent stock transaction reflects the ongoing dynamics at Accolade, Inc. (NASDAQ:ACCD), it's worth examining some key financial metrics and insights provided by InvestingPro to gain a broader perspective on the company's current position.
According to InvestingPro Data, Accolade's market capitalization stands at $256.91 million, with a revenue of $441.03 million for the last twelve months as of Q2 2025. The company has shown a revenue growth of 16.04% over the same period, indicating some positive momentum in its business operations.
However, InvestingPro Tips highlight that Accolade is not currently profitable, with analysts not anticipating profitability in the near term. This aligns with the reported operating income of -$93.68 million and an EBITDA of -$53.62 million for the last twelve months.
The stock's performance has been challenging, with InvestingPro Data showing a 6-month price total return of -58.22% and a year-to-date return of -73.77%. This poor performance is further emphasized by an InvestingPro Tip noting that the stock is trading near its 52-week low.
On a more positive note, InvestingPro Tips indicate that Accolade operates with a moderate level of debt and its liquid assets exceed short-term obligations, which could provide some financial flexibility as the company works towards profitability.
For investors seeking a more comprehensive analysis, InvestingPro offers 10 additional tips for Accolade, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.